GlobeNewswire

Server Technology’s HDOT Cx Future-Proofs Data Center PDU Investments with Flexible, High-Density Data Center Power Distribution Systems

Del

New Era of Dynamic Data Center Power Distribution Units Poised to Retire Stagnant Power Strips as Facility Requirements Continue to Change

RENO, Nev., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Server Technology, a brand of Legrand and a leading provider of intelligent rack power distribution units (PDUs), today unveiled its HDOT Cx. The new data center PDU represents a groundbreaking advancement in rack mount power strips by allowing the outlet to easily conform to any combination of hardware power configuration needs. The HDOT Cx reduces the need for data center managers to constantly purchase new PDUs to support the ever-changing power requirements of expanding data centers. 

As data centers continue to expand, new hardware devices are constantly added to rack-mounted server bays in support of new applications or additional processing abilities. The changing hardware prompts new power configurations and the never-ending cycle of purchasing data center PDUs. Server Technology’s HDOT Cx breaks this cycle with a flexible, rack mounted PDU outlet combination to suit any server rack need.

According to Travis Irons, Director of Engineering at Server Technology, “For the data center manager, a key consideration in choosing a data center PDU which meets the current and future server rack needs, is the number of C13 and C19 outlets that are provided with the unit. HDOT Cx simplifies the decision of what C13/C19 combinations are needed because Cx outlets are both. Data center managers can now take advantage of flexible data center power distribution units and not worry about buying a new unit due to constant equipment refreshes.”

The Cx rack-mounted PDU is UL tested for combination C13 and C19 outlets. All HDOT Cx modules utilize Cx outlets that can accommodate either a C14 or C20 power cable without the need for additional parts or adapters. The complete line of Server Technology’s Smart, Switched, and POPS PDUs can now be configured with versatile HDOT Cx modules. PDUs equipped with HDOT Cx outlets lengthen the PDU life span, reduce the number of PDU SKUs required and provide the peace-of-mind that they can support any new hardware configurations thrown their way.

“For Legrand, the continued success of HDOT was a clear indication that Server Technology understood how to encourage innovation. Designs like HDOT only occur when team members are free to conceptualize without restraint,” said Douglas Fikse, President of Datacenter Power and Control, Legrand North America. “This is precisely why Legrand acquired Server Technology last November. There is something special happening there that cannot be replicated easily. It is no surprise the Server Technology team conceived a design that advances an already successful product with the release of HDOT Cx.”

Build-Your-Own website: byopdu.servertech.com, and it ships within 10 days.

About Server Technology
Server Technology's power strategy experts are trusted to provide Rack PDU solutions for demanding data centers worldwide ranging from small technology startups to Fortune 100 powerhouses. Over 60,000 customers around the world rely on our rack power distribution units and award winning remote power management solutions to increase density, facilitate capacity planning, improve power monitoring, and drive efficiency. Because power is all we do, you will find us in the best cloud and co-location providers, forward thinking labs and telecommunications operations. Server Technology customers consistently rank us as providing the highest quality PDU's, the best customer support and most valuable innovation. Let us show you; we have over 12,000 PDU configurations to fit every data center need and 90% of our PDU's are shipped within 10 days. Only with Server Technology will customers Stay Powered, Be Supported and Get Ahead. www.servertech.com

About Legrand and Legrand, North and Central America
Legrand is a global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for use in commercial, industrial, and residential markets makes it a benchmark for customers worldwide. Innovation for a steady flow of new products with high added value is a prime vector for growth, including, in particular, connected devices stemming from Legrand's global Eliot (Electricity and IoT) program. Legrand reported sales of $6.2 billion(USD) in 2017. Legrand has a strong presence in North and Central America, with a portfolio of well-known market brands and product lines that includes AFCO Systems, C2G, Cablofil, Chief, Da-Lite, Electrorack, Finelite, Luxul, Middle Atlantic Products, Milestone AV, Nuvo, OCL, On-Q, Ortronics, Pass & Seymour, Pinnacle, Projecta, QMotion, Quiktron, Raritan, Sanus, Server Technology, Solarfective, Vaddio, Vantage, Wattstopper, and Wiremold. Legrand is listed on Euronext Paris and is a component stock of indexes including the CAC40, FTSE4Good, MSCI World, ASPI, Corporate Oekom Rating, and DJSI (ISIN code FR0010307819). www.legrand.us

For more information, contact:
Server Technology
Betsey Rogers
Public Relations
BridgeView Marketing
1-603-821-0809
betsey@bridgeviewmarketing.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t

CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00Pressemelding

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos

Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00Pressemelding

Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00Pressemelding

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated

GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12Pressemelding

SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no

Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00Pressemelding

OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist